Дисліпідемія

Primary causes are single or multiple gene mutations that result either in overproduction or defective clearance of triglycerides and LDL or in underproduction or excessive clearance of HDL (see table Genetic (Primary) Dyslipidemias).

Secondary causes contribute to many cases of dyslipidemia in adults.

The most important secondary cause of dyslipidemia in high-resource countries is

• A sedentary lifestyle with excessive dietary intake of total calories, saturated fat, cholesterol, and trans fats

Trans fats are polyunsaturated or monounsaturated fatty acids to which hydrogen atoms have been added; they are used in some processed foods and are as atherogenic as saturated fat.

Other common secondary causes of dyslipidemia include

• Diabetes mellitus

• Chronic kidney disease

• Primary biliary cirrhosis and other cholestatic liver diseases

• Hypothyroidism

• Alcohol overuse

• Medications, such as thiazides, beta-blockers, retinoids, highly active antiretroviral agents, cyclosporine, tacrolimus, progestins, and glucocorticoids; oral estrogens cause a mixed effect (decrease LDL-C and increase HDL-C, but also increase TGs)

Secondary causes of low levels of HDL-C include cigarette smoking, anabolic steroids, HIV infection, and nephrotic syndrome.

Diabetes is an especially significant secondary cause because patients tend to have an atherogenic combination of high TGs; high small, dense LDL fractions; and low HDL (diabetic dyslipidemia, hypertriglyceridemic hyperapo B). Patients with type 2 diabetes are especially at risk. The combination may be a consequence of obesity, poor control of diabetes, or both, which may increase circulating free fatty acids (FFAs), leading to increased hepatic very-low-density lipoprotein (VLDL) production. TG-rich VLDL then transfers TG and cholesterol to LDL and HDL, promoting formation of TG-rich, small, dense LDL and clearance of TG-rich HDL. Diabetic dyslipidemia is often exacerbated by the increased caloric intake and physical inactivity that characterize the lifestyle of some patients with type 2 diabetes. Women with diabetes may be at special risk of cardiac disease as a result of this form of dyslipidemia.

Total cholesterol (TC), triglycerides (TGs), and HDL-C are measured directly. TC and TG values reflect cholesterol and TGs in all circulating lipoproteins, including chylomicrons, VLDL, intermediate-density lipoprotein (IDL), LDL, and HDL. TC values can vary by 10% and TGs by up to 25% day-to-day even in the absence of a disorder.

TC and HDL-C may be measured in the nonfasting state, but most patients should have all lipids measured while fasting (usually for 12 hours) for maximum accuracy and consistency.

Testing should be postponed if a patient has an acute illness, because TG and lipoprotein(a) levels increase and cholesterol levels decrease in inflammatory states. Also, lipid profiles can vary for about 30 days after an acute myocardial infarction (MI); however, results obtained within 24 hours after MI are usually reliable enough to guide initial lipid-lowering therapy.

LDL-C values are most often calculated as the amount of cholesterol not contained in HDL and VLDL. VLDL is estimated by TG ÷ 5 because the cholesterol concentration in VLDL particles is usually one fifth of the total lipid in the particle. Thus, the Friedewald formula estimates LDL-C as follows:

The calculated LDL cholesterol value incorporates measures of all non-HDL and nonchylomicron cholesterol, including that in IDL and lipoprotein (a) (Lp(a)).

For patients who have elevated TG levels, errors in estimating VLDL-C are magnified while using the constant factor of 5. The Martin-Hopkins equation may be used to obtain a more reliable estimate of LDL-C. The constant factor of 5 is replaced with a novel factor based on a patient's non-HDL-C and TG values (1). The novel factor is an adjustable factor that is based on the patient's non-HDL-C and TG levels and is derived from a table. Both the Friedewald and Martin-Hopkins equations were developed and validated for fasting patients with serum TG levels < 400 mg/dL (< 4.5 mmol/L). 

The Martin-Hopkins equation is as follows:

LDL-C can also be measured directly using plasma ultracentrifugation, which separates chylomicrons and VLDL fractions from HDL-C and LDL-C, and by an immunoassay method. Direct measurement may be useful in some patients with elevated TGs, but these direct measurements are not usually necessary.

Клінічний калькулятор

Рівняння Мартіна для ліпопротеїнів низької щільності (Х-ЛПНЩ)

Клінічний калькулятор

Ліпопротеїни дуже низької щільності (ЛПДНЩ)

In some patients, additional lipid tests should be done.

Lp(a) levels and C-reactive protein levels should be measured in patients with premature atherosclerotic cardiovascular disease, cardiovascular disease (even if they have lower risk lipid levels; see table Cholesterol Levels and Cardiovascular Risk), or high LDL-C levels refractory to drug therapy. Lp(a) levels may also be directly measured in patients with borderline-high LDL-C levels to determine whether drug therapy is warranted.

Measurements of LDL particle number or apoprotein B-100 (apo B) is useful in patients with elevated TGs and the metabolic syndrome. Apo B provides similar information to LDL particle number because there is one apo B molecule for each LDL particle. Apo B measurement includes all atherogenic particles, including remnants and Lp(a).

Apo B value reflects all non-HDL-C (in VLDL, IDL, and LDL) and is more predictive of CAD risk than LDL-C. Non-HDL-C (TC − HDL-C) is also more predictive of CAD risk than LDL-C, especially in patients with hypertriglyceridemia.

Клінічний калькулятор

Рівняння Фрідевальда для ліпопротеїнів низької щільності (Х-ЛПНЩ, одиниці СІ)

Клінічний калькулятор

Рівняння Фрідевальда для ліпопротеїнів низької щільності (Х-ЛПНЩ)

Tests for secondary causes of dyslipidemia should be done in most patients with newly diagnosed dyslipidemia and repeated when a component of the lipid profile has inexplicably changed for the worse. Such tests include measurements of

• Creatinine

• Fasting glucose and/or glycosylated hemoglobin (HbA1C)

• Liver enzymes

• Thyroid-stimulating hormone (TSH)

• Urinary protein

1. 1. Martin SS, Blaha MJ, Elshazly MB, et al: Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 310(19):2061-2068, 2013. doi:10.1001/jama.2013.280532

Most physicians recommend screening per the 2012 National Heart Lung and Blood Institute Guidelines (1) as follows

• Children with risk factors (eg, diabetes, hypertension, family history of severe hyperlipidemia or premature CAD): Fasting lipid profile once at age 2 to 8

• Children with no risk factors: Non-fasting or fasting lipid profile once before puberty (usually age 9 to 11) and once more at age 17 to 21

Adults should be screened at age 20 (2, 3) and every 5 years thereafter.

An age to discontinue screening has not been established, but evidence supports screening of patients into their 80s, especially if they have atherosclerotic cardiovascular disease (4).

Patients with an extensive family history of heart disease—heart attack, stroke, or coronary artery disease before age 55 (in men) or age 65 (in women) without known risk factors, such as high LDL, smoking, diabetes, or obesity, or known family history of high Lp(a)—should also be screened by measuring Lp(a) levels.

1. 1. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. 2011.

2. 2. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. J Am Coll Cardiol 63:2935–2959, 2014. doi: 10.1016/j.jacc.2013.11.005

3. 3. Grundy SM, Stone NJ, Bailey AL, et al: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139: e1082–e1143, 2019. doi: 10.1161/CIR.0000000000000625

4. 4. Kleipool EE, Dorresteijn JA, Smulders YM, et al: Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach. Heart 106(4):261-266, 2020. doi:10.1136/heartjnl-2019-315600

The main goal for dyslipidemia treatment is prevention of atherosclerotic cardiovascular disease (ASCVD), including acute coronary syndromes, stroke, transient ischemic attack, or peripheral arterial disease presumed caused by atherosclerosis. Treatment is indicated for all patients with ASCVD (secondary prevention) and for some without (primary prevention).

Treatment of children is controversial because there is no evidence that lowering lipid levels in childhood effectively prevents heart disease in adulthood. Moreover, the safety and effectiveness of long-term lipid-lowering treatment in children are unknown. Nevertheless, the American Academy of Pediatrics (AAP) recommends treatment for some children who have elevated LDL-C levels. Children with heterozygous familial hypercholesterolemia should be treated beginning at age 8 to 10 years. Children with homozygous familial hypercholesterolemia require diet, medications, and often LDL apheresis to prevent premature death; treatment is begun when the diagnosis is made.

Treatment options depend on the specific lipid abnormality, although different lipid abnormalities often coexist. In some patients, a single abnormality may require several therapies; in others, a single treatment may be adequate for several abnormalities. Treatment should always include treatment of hypertension and diabetes and smoking cessation. Treatment should also include daily low-dose aspirin in patients age 40 to 79 years with a low risk of bleeding and with a 10-year risk of myocardial infarction or death due to CAD of ≥ 20%. In general, treatment options for men and women are the same.

Клінічний калькулятор

Оцінювання серцево-судинного ризику (10-річного, переглянуті об’єднані когортні рівняння 2018 р.)

For all individuals, the prevention of ASCVD requires an emphasis on a heart-healthy lifestyle, particularly diet and exercise. Other options to lower LDL-C in all age groups include medications, dietary supplements, and procedural interventions. Many of these options are also effective for treating other lipid abnormalities.

Dietary changes help to maintain ideal body weight and provide other benefits. These changes include

• Decreasing intake of saturated fats and cholesterol

• Increasing the proportion of dietary fiber and complex carbohydrates

Referral to a dietitian is often useful.

Exercise lowers LDL-C in some people and also helps maintain ideal body weight.

Dietary changes and exercise should be used whenever feasible, but American Heart Association (AHA)/American College of Cardiology (ACC) guidelines recommend also using drug therapy for certain groups of patients after discussion of the risks and benefits of statin therapy (1).

For drug therapy in adults, the AHA/ACC Guidelines recommend treatment with a statin for 4 groups of patients, comprised of those with any of the following:

• Clinical ASCVD

• LDL-C ≥ 190 mg/dL (≥ 4.9 mmol/L)

• Age 40 to 75 years, with diabetes and LDL-C 70 to 189 mg/dL (1.8 to 4.9 mmol/L)

• Age 40 to 75 years, with LDL-C 70 to 189 mg/dL (1.8 to 4.9 mmol/L), and an estimated 10-year risk of ASCVD ≥ 7.5%

Risk of ASCVD is estimated using the pooled cohort risk assessment equations. This risk calculator is based on sex, age, race, total and HDL-C, systolic and diastolic blood pressure, diabetes and smoking status, and use of antihypertensives or statins.

Increased lifetime risk (identified using the AHA/ACC risk calculator) is relevant because 10-year risk may be low in younger patients, in whom longer-term risk should be taken into account.

When considering whether to give a statin, clinicians may also take into account other factors, including

• LDL-C ≥ 160 mg/dL (4.1 mmol/L)

• Family history of premature ASCVD (ie, age of onset < 55 years in a male first-degree relative, or < 65 years in a female first-degree relative)

• High-sensitivity C-reactive protein ≥ 2 mg/L (≥ 19 nmol/L)

• Coronary artery calcium score ≥ 300 Agatston units (or ≥ 75th percentile for the patient's demographic)

• Ankle-brachial index < 0.9

• Increased lifetime risk

Statins are the treatment of choice for LDL-C reduction because evidence has demonstrated that they reduce cardiovascular morbidity and mortality (2). Other classes of lipid-lowering drugs are not the first choice for treating elevated LDL-C because they have not demonstrated equivalent efficacy for decreasing ASCVD.

Statins inhibit hydroxymethylglutaryl CoA reductase, a key enzyme in cholesterol synthesis, leading to up-regulation of LDL receptors and increased LDL clearance. They reduce LDL-C by up to 60% and produce small increases in HDL-C and modest decreases in TGs. Statins also appear to decrease intra-arterial inflammation, systemic inflammation, or both by stimulating production of endothelial nitric oxide and may have other beneficial effects.

Statin therapy is classified as high-, moderate-, or low-intensity and is given based on treatment group and age (see table Statins for ASCVD Prevention). The choice of statin depends on the patient's co-morbidities, other drugs, risk factors for adverse events, statin intolerance, cost, and patient preference.

Adverse effects with statins are uncommon but include liver enzyme elevations and myositis or rhabdomyolysis. Liver enzyme elevations are uncommon, and serious liver toxicity is extremely rare. Symptoms or severe adverse effects involving muscle occur in up to 10% of patients taking statins and may be dose-dependent. Muscle symptoms can occur without muscle enzyme (eg, creatine kinase) elevation. Adverse effects are more common among older patients, patients with several disorders, and patients taking several drugs. In some patients, changing from one statin to another or lowering the dose (after temporarily discontinuing the drug) relieves the problem. Muscle toxicity seems to be most common when some of the statins are used with drugs that inhibit cytochrome P3A4 (eg, macrolide antibiotics, azole antifungals, cyclosporine) and with fibrates, especially gemfibrozil. Statins are contraindicated during pregnancy and lactation.

In patients with ASCVD, risk reduction increases with decreasing LDL-C levels. Thus, initial treatment is a statin at maximally tolerated dose with the goal of lowering LDL-C by > 50% (high-intensity therapy). For very high-risk patients with ASCVD (eg, those with a recent myocardial infarction or unstable angina or with high-risk comorbidities such as diabetes), a LDL-C level > 70 mg/dL (> 1.2 mmol/L) despite maximal statin therapy should prompt the addition of ezetimibe or a PCSK9 inhibitor (eg, evolocumab, alirocumab). These therapies have been proven to reduce major adverse cardiovascular events in conjunction with statin therapy in large clinical outcome trials (3, 4).

Non-statin medications also have a place in lowering LDL-C (see table Non-Statin Lipid–Lowering Drugs). The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies provides guidance to clinicians on the role of non-statin therapy in both primary and secondary prevention of ASCVD (5). Statins are generally first-line medications, but in patients with statin intolerance, or those who are not able to achieve target LDL-C levels despite statin use, non-statin medications are used.

The adenosine triphosphate citrate lyase inhibitor, bempedoic acid impairs cholesterol synthesis in the liver and increases LDL receptors. It lowers LDL-C by 15 to 17% (6, 7). Bempedoic acid is especially useful in patients with statin-associated muscle adverse effects because it does not cause muscle pain or weakness. It can be used as monotherapy or as an add-on to other lipid-lowering therapy. Risks include hyperuricemia and tendon rupture.

Bile acid sequestrants (cholestyramine, colestipol, colesevelam) block intestinal bile acid reabsorption, forcing up-regulation of hepatic LDL receptors to recruit circulating cholesterol for bile synthesis. They have been shown to reduce cardiovascular mortality. Bile acid sequestrants are usually used with statins or with nicotinic acid to augment LDL-C reduction. They are the drugs of choice for women who are or are planning to become pregnant. Statins are contraindicated in pregnancy because they maybe teratogenic due to the interruption of cholesterol synthesis, which is essential in fetal development. Bile acid sequestrants are safe, but their use is limited by adverse effects of bloating, nausea, cramping, and constipation. They may also increase TGs, so their use is contraindicated in patients with hypertriglyceridemia. Cholestyramine, colestipol, and colesevelam (but to a lesser degree), interfere with absorption of other drugs—notably thiazides, beta-blockers, warfarin, digoxin, and thyroxine—an effect that can be decreased by administration at least 4 hours before or 1 hour after other drugs. Bile acid sequestrants should be given with meals to increase their efficacy.

The cholesterol absorption inhibitor ezetimibe inhibits intestinal absorption of cholesterol and phytosterol. Ezetimibe usually lowers LDL-C by 15 to 20% and causes small increases in HDL-C and a mild decrease in triglycerides. Ezetimibe can be used as monotherapy in patients intolerant to statins or added to statins for patients taking maximum statin doses with persistent LDL-C elevation. Adverse effects are infrequent.

PCSK9 monoclonal antibodies (alirocumab, evolocumab) are available as subcutaneous injections given once or twice per month. These drugs keep PCSK9 from attaching to LDL receptors, leading to improved function of these receptors. LDL-C is lowered by 40 to 70%. Cardiovascular outcomes trials with evolocumab and alirocumab showed a decrease in cardiovascular events in patients with prior atherosclerotic cardiovascular disease (3).

SiRNA targeting PCSK9 is given as a subcutaneous injection every 6 months. Inclisiran inhibits PCSK9 production in the liver, thereby prolonging activity of LDL receptors and lowering LDL-C levels. Although LDL-C is lowered, cardiovascular outcome trials with inclisiran are ongoing. Inclisiran can be used as an adjunct to diet and maximally tolerated statin therapy for patients with ASCVD or heterozygous familial hypercholesterolemia.

Dietary supplements that lower LDL-C levels include fiber supplements and commercially available margarines and other products containing plant sterols (sitosterol, campesterol) or stanols. Fiber supplements decrease cholesterol levels in multiple ways, including decreased absorption and increased excretion. Oat-based fiber supplements can decrease total cholesterol by up to 18%. Plant sterols and stanols decrease cholesterol absorption by displacing cholesterol from intestinal micelles and can reduce LDL-C by up to 10% without affecting HDL-C or TGs.

Cholesterylester transfer protein inhibitors are a class of drugs that are under investigation and that may simultaneously raise HDL-C and lower LDL-C. Cholesterylester transfer protein (CETP) is a plasma glycoprotein produced in the liver and adipose tissue that circulates in the blood bound primarily to HDL, which mediates the transfer of cholesteryl esters from HDL to ApoB containing particles.

Childhood risk factors besides family history and diabetes include cigarette smoking, hypertension, low HDL-C (< 35 mg/dL [< 0.9 mmol/L]), obesity, and physical inactivity.

The American Heart Association recommends dietary treatment for children with LDL-C > 110 mg/dL (> 2.8 mmol/L) (8).

Drug therapy is recommended for children > 8 years and with either of the following:

• Poor response to dietary therapy, LDL-C ≥ 190 mg/dL (≥ 4.9 mmol/L), and no family history of premature cardiovascular disease

• LDL-C ≥ 160 mg/dL (≥ 4.13 mmol/L) and a family history of premature cardiovascular disease or ≥ 2 risk factors for premature cardiovascular disease

Medications used in children include many of the statins. Children with familial hypercholesterolemia may require a second drug to achieve LDL-C reduction of at least 50%.

Although it is unclear whether elevated TGs independently contribute to cardiovascular disease, they are associated with multiple metabolic abnormalities that contribute to coronary artery disease (eg, diabetes, metabolic syndrome). Consensus is emerging that lowering elevated TGs is beneficial. No target goals exist, but levels < 150 mg/dL (< 1.7 mmol/L) are generally considered desirable. No guidelines specifically address treatment of elevated TGs in children.

The overall treatment strategy is to first implement lifestyle changes, including exercise, weight loss, and avoidance of concentrated dietary sugar and alcohol. Intake of 2 to 4 servings/week of marine fish high in omega-3 fatty acids may be effective, but the amount of omega-3 fatty acids is often lower than needed; supplemental doses may be helpful. In patients with diabetes, glucose levels should be tightly controlled. If these measures are ineffective, lipid-lowering drugs should be considered. Patients with very high TG levels (> 1,000 mg/dL [> 11 mmol/L]) may need to begin drug therapy at diagnosis to more quickly reduce the risk of acute pancreatitis.

Fibrates reduce TGs by about 50%. They appear to stimulate endothelial lipoprotein lipase (LPL), leading to increased fatty acid oxidation in the liver and muscle and decreased hepatic VLDL synthesis. They also increase HDL-C by up to 20%. Fibrates can cause gastrointestinal adverse effects, including dyspepsia, abdominal pain, and elevated liver enzymes. They uncommonly cause cholelithiasis. Fibrates may potentiate muscle toxicity when used with statins and potentiate the effects of warfarin.

Statins can be used in patients with TGs < 500 mg/dL (< 5.65 mmol/L) if LDL-C elevations are also present; statins may reduce both LDL-C and TGs through reduction of VLDL. If only TGs are elevated, fibrates are the drug of choice.

Omega-3 fatty acids in high doses (1 to 6 g a day of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) can be effective in reducing TGs. The omega-3 fatty acids EPA and DHA are the active ingredients in marine fish oil or omega-3 capsules. Adverse effects include eructation and diarrhea. These effects may be decreased by giving the fish oil capsules with meals in divided doses (eg, twice a day or 3 times a day). Omega-3 fatty acids can be a useful adjunct to other therapies. Prescription omega-3 fatty acid preparations are indicated for TG levels > 500 mg/dL (> 5.65 mmol/L).

The Apo CIII inhibitor (an antisense inhibitor of apo CIII), volanesorsen, is available in some countries. It lowers triglyceride levels in patients with severely elevated TG levels, including people with lipoprotein lipase deficiency. It is given as a weekly injection.

Although higher HDL-C levels predict lower cardiovascular risk, it is not clear whether treatments to increase HDL-C levels decrease risk of death. Guidelines in the Third Report of the NCEP Expert Panel define low HDL-C as < 40 mg/dL [< 1.04 mmol/L]; the guidelines do not specify an HDL-C target level and recommend interventions to raise HDL-C only after LDL-C targets have been reached (9). Treatments for LDL-C and TG reduction often increase HDL-C, and the 3 objectives can sometimes be achieved simultaneously.

No guidelines specifically address treatment of low HDL-C in children.

Treatment includes lifestyle changes such as an increase in exercise and weight loss. Alcohol raises HDL-C but is not routinely recommended as a therapy because of its many other adverse effects. Drugs may be successful in raising levels when lifestyle changes alone are insufficient, but it is uncertain whether raising HDL-C levels reduces mortality.

Nicotinic acid (niacin) is the most effective drug for increasing HDL-C. Its mechanism of action is unknown, but it appears to both increase HDL-C production and inhibit HDL-C clearance; it may also mobilize cholesterol from macrophages. Niacin also decreases TGs and, in doses of 1500 to 2000 mg a day, reduces LDL-C. Niacin causes flushing, pruritus, and nausea; premedication with low-dose aspirin may prevent these adverse effects. Extended-release preparations cause flushing less often. However, most over-the-counter slow-release preparations are not recommended; an exception is polygel controlled-release niacin. Niacin can cause liver enzyme elevations and occasionally liver failure, insulin resistance, and hyperuricemia and gout. It may also increase homocysteine levels. The combination of high doses of niacin with statins may increase the risk of myopathy. In patients with average LDL-C and below-average HDL-C levels, niacin combined with statin treatment may be effective in preventing cardiovascular disorders. In patients treated with statins to lower LDL-C to < 70 mg/dL (< 1.8 mmol/L), niacin does not appear to have added benefit and may cause increased adverse effects, including ischemic stroke.

Fibrates increase HDL-C. Fibrates may decrease cardiovascular risk in patients with TGs > 200 mg/dL (> 2.26 mmol/L) and HDL-C < 40 mg/dL (< 1.04 mmol/L).

The usual approach in patients with elevated Lp(a) is to lower LDL-C aggressively. LDL apheresis has been used to lower Lp(a) in patients with high Lp(a) levels and progressive vascular disease.

The upper limit of normal for Lp(a) is about 30 mg/dL (75 nmol/L), but values in African Americans tend to be higher. Few data exist to guide the treatment of elevated Lp(a) or to establish treatment efficacy. Niacin is the only drug that directly decreases Lp(a); it can lower Lp(a) by > 20% at higher doses. There are several RNA-based therapies that lower Lp(a) levels in clinical development.

Treatment of diabetic dyslipidemia should always involve lifestyle changes and statins to reduce LDL-C. To decrease the risk of pancreatitis, fibrates can be used to decrease TGs when levels are > 500 mg/dL (> 5.65 mmol/L). Metformin lowers TGs, which may be a reason to choose it over other oral antihyperglycemic drugs when treating diabetes. Some thiazolidinediones (TZDs) increase both HDL-C and LDL-C. Some TZDs also decrease TGs. These antihyperglycemic drugs should not be chosen over lipid-lowering drugs to treat lipid abnormalities in patients with diabetes but may be useful adjuncts. Patients with very high TG levels and less than optimally controlled diabetes may have a better response to insulin than to oral antihyperglycemic drugs.

Treatment of dyslipidemia in patients with hypothyroidism, chronic kidney disease, liver disease, or a combination of these disorders involves treating the underlying disorders primarily and lipid abnormalities secondarily. Abnormal lipid levels in patients with low-normal thyroid function (high-normal TSH levels) improve with hormone replacement. Reducing the dosage of or stopping drugs that cause lipid abnormalities should be considered.

Lipid levels should be monitored periodically after starting treatment. No data support specific monitoring intervals, but measuring lipid levels 2 to 3 months after starting or changing therapies and once or twice yearly after lipid levels are stabilized is common practice.

Liver and severe muscle toxicity with statin use occurs in 0.5 to 2% of all users. Routine monitoring of liver enzyme levels is not necessary, and routine measurement of creatine kinase (CK) is not useful to predict the onset of rhabdomyolysis. Muscle enzyme levels need not be checked regularly unless patients develop myalgias or other muscle symptoms. If statin-induced muscle damage is suspected, statin use is stopped and CK may be measured. When muscle symptoms subside, a lower dose or a different statin can be tried. If symptoms do not subside within 1 to 2 weeks of stopping the statin, another cause should be sought for the muscle symptoms (eg, polymyalgia rheumatica).

1. 1. Grundy SM, Stone NJ, Bailey AL, et al: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139: e1082–e1143, 2019. doi: 10.1161/CIR.0000000000000625

2. 2. US Preventive Services Task Force, Mangione CM, Barry MJ, et al: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 328(8):746-753, 2022. doi:10.1001/jama.2022.13044

3. 3. Sabatine MS, Giugliano RP, Keech AC, et al: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722, 2017. 15

4. 4. Schwartz GG, Steg PG, Szarek M, et al: Alirocumab and cardiovascular outcomes after acute coronary syndrome. New Engl J Med 379:2097–2107, 2018. doi: 10.1056/NEJMoa1801174.

5. 5. Writing Committee, Lloyd-Jones DM, Morris PB, et al:. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee [published correction appears in J Am Coll Cardiol 2023 Jan 3;81(1):104]. J Am Coll Cardiol 80(14):1366-1418, 2022. doi:10.1016/j.jacc.2022.07.006

6. 6. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial [published correction appears in JAMA. 2020 Jan 21;323(3):282]. JAMA 2019;322(18):1780-1788. doi:10.1001/jama.2019.16585

7. 7. Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 2019;380(11):1022-1032. doi:10.1056/NEJMoa1803917

8. 8. de Ferranti SD, Steinberger J, Ameduri R, et al: Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation 139(13):e603-e634, 2019. doi:10.1161/CIR.0000000000000618

9. 9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25):3143-3421, 2002.